GSK 3β Kaninchen-pAb von ELK Biotechnology
Know who made it. See the evidence. Buy through one marketplace.
GSK 3β Kaninchen-pAk ist ein ELK Biotechnology-Antikörper für Forschungsabläufe, die GSK 3β betreffen.
Die Glykogen-Synthase-Kinase 3 beta, auch bekannt als GSK3B, ist ein Enzym, das beim Menschen durch das GSK3B-Gen kodiert wird.
| Beschriftungen der Validierungsnachweise | Western-Blot-Analyse von 1) Mäusehirngewebe, 2) Mäuseherzgewebe, 3) Rattenhirngewebe, 4) Rattenherzgewebe mit GSK 3β Kaninchen-pAk EA169, verdünnt auf 1:2.000. | Immunhistochemische Analyse von paraffineingebettetem Mäuselungengewebe unter Verwendung von GSK 3β (EA169) Kaninchen-pAk, verdünnt auf 1:500. |
|---|
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Arten | WB | IHC | IF | ELISA | IP | FCM | ChIP |
|---|---|---|---|---|---|---|---|
| Ratte | |||||||
| Maus |
This product is manufactured by ELK Biotechnology and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
